Clinton vows price controls, generic biologics in healthcare plan

Share this article:
Clinton vows price controls on Rx drugs
Clinton vows price controls on Rx drugs
Sen. Hillary Clinton unveiled her healthcare plan, promising to cover all Americans if elected president  –  and taking a few swipes at the pharmaceutical and insurance industries.

“The special interests are having a field day,” she said, describing the Medicare prescription drug benefit as a bonanza for Big Pharma.

The front-running candidate for the Democratic presidential nomination would impose price controls on drugs (“to get prices down in accordance with those in Canada”) and speed the introduction of generic biologics as part of her scheme to cover all Americans  –  in addition to mandating health insurance, making plans portable, combating insurer discrimination against high-risk enrollees and offering small businesses tax credits as incentive to cover their employees. Every American, she said, would have access to the same menu of insurance options that Congress does, including a public plan that would compete with private insurers.

“It's a public-private partnership that provides more choices,” she said, speaking at Broadlawns Medical Center in Des Moines, Iowa.

Clinton boasted that she still bore the scars of her failed 1994 effort to pass universal healthcare legislation, and so did her speech today. Her earlier plan was savaged by the healthcare industry in ads and opinion columns warning that consumers would no longer be able to choose their own doctors if she had her way. The new plan is dubbed “American Health Choices Plan,” and the word “Choice” was a mantra in her speech today.

“Today's plan is simpler but still bold,” she said. “This is not government-run healthcare. There will be no new bureaucracies, and you can keep your doctors and your insurance, if you like it.”
Share this article:
You must be a registered member of MMM to post a comment.


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...